Welcome to the e-CCO Library!

P678 Effect of accelerated infliximab induction on short-term outcomes of paediatric acute severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.B. Coronel-Arismendi, G. Pujol Muncunill, B. Minguez-Rodríguez, S. Feo-Ortego, L.N. Guevara-Caviedes, V. Vila-Miravet, F.J. Martin De Carpi

Created: Thursday, 30 January 2020, 10:12 AM
P678: Definition of a microbial signature as a predictor of post-surgical recurrence in patients with Crohn's disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Oliver, L.(1);Amoedo, J.(1);Julià, D.(2);Camps, B.(3);Ramió-Pujol, S.(1);Malagón, M.(1);Torres, P.(4);Domènech, E.(4);Guardiola, J.(3);Serra-Pagès, M.(1);Garcia-Gil, J.(5);Aldeguer, X.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P678: Did toxicity profile of azathioprine changed within the last 10 years: comparative 17 years data from a single tertiary IBD center
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bozcan S., Hatemi I., Yıldırım S., Demir N., Erzin Y., Celik A.F.

Created: Wednesday, 20 February 2019, 10:36 AM
P678: Rare and severe complications in paediatric Inflammatory Bowel Disease: results of 5 years of international collaboration through the PIBD-SETQuality Safety Registry
Year: 2022
Source: ECCO'22
Authors: Klomberg, R.(1);Kemos, P.(2);Chondrou, P.(2);Croft, N.(2);de Ridder, L.(1);
Created: Friday, 11 February 2022, 3:56 PM
P678: Risk of malnutrition in patients with inflammatory bowel diseases: Results from an Italian multi-centre observational cross-sectional study
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Viganò1*, A. Losco2, I. Bergna1, G. Meucci3, A. Amato4, GSMII (Gruppo di Studio per le Malattie Infiammatorie Intestinali)

Created: Thursday, 21 February 2019, 9:14 AM
P678: Treatment of moderate to severe UC patients with new 5ASA tablets
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Laoun*1, R. Hofmann2

Created: Friday, 22 February 2019, 9:41 AM
P678: Ustekinumab therapy improves the nutritional status in patients with Crohn's Disease. A prospective study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: BertaniMD, L.(1,2)*;D'Alessandro, C.(1);Fornili, M.(3);Coppini, F.(1);Zanzi, F.(1);Carmisciano, L.(3);Geri, F.(1);Baiano Svizzero, G.(4);Ceccarelli, L.(4);Mumolo, M.G.(4);Baglietto, L.(3);Bellini, M.(1);Costa, F.(4);De Bortoli, N.(1);
Created: Friday, 14 July 2023, 11:12 AM
P679 What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Cerpa Arencibia, C. Suarez Ferrer, J. Poza Cordón, E. Martín Arranz, L. Ramírez, M.D. Martín Arranz

Created: Thursday, 30 January 2020, 10:12 AM
P679: Development of a novel auto-injector of subcutaneous CT-P13 infliximab: Phase I randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Schreiber*1, S. Ben-Horin2, B. D. Ye3, R. Westhovens4, D. H. Yoo5, S. J. Lee6, J. H. Suh6, J. H. Byeon6, W. Reinisch7

Created: Friday, 22 February 2019, 9:41 AM
P679: Inflammatory Bowel Disease and cancer risk in the IBSEN study after 30 years of follow-up.
Year: 2022
Source: ECCO'22
Authors: Follin-Arbelet, B.(1);Småstuen Cvancarova, M.(2);Hovde, Ø.(3);Jelsness-Jørgensen, L.P.(4);Moum, B.(2);
Created: Friday, 11 February 2022, 3:56 PM
P679: Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gompertz M., Alfaro I., Ricart E., Lόpez A., Panés J., Gallego M., Barastegui R., Giner A., Vara A., Masamunt M., Ordás I.

Created: Wednesday, 20 February 2019, 10:36 AM
P679: Is the burden of obesity in IBD bigger than just weight?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Madigan, S.(1);Mountifield, R.(1)*;Barnes, A.(1);
Created: Friday, 14 July 2023, 11:12 AM
P679: Risk factors for disease relapse after stepping down from combination to anti-TNF monotherapy in children with IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Yerushalmy-Feler*, S. Cohen

Created: Thursday, 21 February 2019, 9:14 AM
P679: The keystone bacterium Christensenella minuta improves colitis in in vivo preclinical Inflammatory Bowel Disease models
Year: 2021
Source: ECCO'21 Virtual
Authors: Kropp, C.(1);Le Corf, K.(2);Relizani, K.(2);Tambosco, K.(1);Martinez, C.(2);Chain, F.(1);Rawadi, G.(2);Langella, P.(1);Claus, S.(2);Martin, R.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P680: A real-life experience of Crohn's Disease Exclusion Diet use at disease onset and as an add-on therapy in pediatric Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Scarallo, L.(1)*;Fioretti, L.(1);Pochesci, S.(1);Pierattini, V.(2);Banci, E.(2);De Blasi, A.(1);Di Paola, M.(1);Lionetti, P.(1,3);
Created: Friday, 14 July 2023, 11:12 AM
P680: Epidemiology of Inflammatory Bowel Disease in Poland 2009-2020: nationwide data
Year: 2022
Source: ECCO'22
Authors: Zagórowicz, E.S.(1);Walkiewicz, D.(2);Kucha, P.(1);Perwieniec, J.(2);Maluchnik, M.(2,3);Wieszczy, P.(4);Reguła, J.(4);
Created: Friday, 11 February 2022, 3:56 PM
P680: Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Ghosh*1, B. C. Kramer2, C. Gasink2, D. Jacobstein3, O. J. Adedokun3, L-L. Gao3, P. Rutgeerts4, B. E. Sands5

Created: Friday, 22 February 2019, 9:41 AM
P680: Machine learning (ML) in RCU-operated patients: Can we predict postoperative complications?
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Sofo*, P. Caprino, A.E. Potenza, F. Sacchetti, C.A. Schena

Created: Thursday, 21 February 2019, 9:14 AM
P680: Quality of sex life in patients with inflammatory bowel disease: the gastroenterologists' perspective
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Rivière P., Laharie D., Zerbib F., Poullenot F.

Created: Wednesday, 20 February 2019, 10:36 AM